Global stem cells group and associate Burton Feinerman M.D. have announced plans to offer innovative stem cell therapies to treat patients with specific neurodegenerative conditions.
MIAMI AND TAMPA, FLA. (PRWEB) AUGUST 24, 2015
Global Stem Cells Group, has announced plans to collaborate with regenerative medicine specialist Burton Feinerman M.D. to offer new stem cell therapies that combine adult stem cells derived from adipose tissue, bone marrow and peripheral blood with differentiated cells and transference factors, using patented protocols developed by Feinerman.
The treatment protocols will target specific neurodegenerative conditions that primarily affect the neurons in the brain. Neurons are critical components of the nervous system, which includes the brain and spinal cord. When they become damaged die, neurons don’t reproduce or replace themselves. Examples of neurodegenerative diseases include Alzheimer’s and Parkinson’s disease.
Neurodegenerative diseases are incurable and debilitating conditions that lead to the progressive degeneration or death of nerve cells, causing difficulty with movement or mental function (dementia). According to a March, 2015 World Health Organization report, dementias are responsible for the greatest burden of disease with Alzheimer’s representing approximately 60-70 percent of cases.
Feinerman is a physician and research scientist specializing in stem cell therapies, ant-aging medicine and gene therapies to treat a variety of conditions and diseases. He is a member of the GSCG Advisory Board.
For more information on innovative stem cell therapies, visit the Global Stem Cells Group Website, email firstname.lastname@example.org, or call 305-224-1858.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
To learn more about Global Stem Cells Group, Inc.’s companies and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
About Burton Feinerman, M.D.:
Burton Feinerman, M.D. an internationally recognized expert in stem cell and gene therapy, helped pioneer the earliest patents for regenerative medicine therapies. He has dedicated his medical career to improving the lives of patients through regenerative medicine.
Feinerman earned a medical degree from New York Medical College and completed his fellowship at the renowned Mayo Clinic in Rochester, Minnesota. He has been practicing medicine for more than half a century and has dedicated his practice to bettering the lives of his patients through regenerative medicine. Feinerman believes in challenging the incurable with regenerative medicine, and providing a new pathway to overall health and longevity.
Feinerman is a highly respected board certified physician and a member of numerous medical societies including the Society of Apheresis, the Society of Bone Marrow Blood Transplantation, the International Society of Cellular Therapy, the Society for Cranial Transplantation and Brain Repair, the Society for Cardiac Translational Therapy. He is a member of the Global Stem Cells Group Advisory Board.